SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Study did not meet key efficacy measures or internal hurdle rate for continued development Systemic

CLDX

Related stories